Rezultati - Zeynep Eroglu

Refine Results
  1. 1
    Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy

    Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy od Zeynep Eroglu, Antoni Ribas

    Izdano 2015
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  2. 2
    Human Epidermal Growth Factor Receptor Family-Targeted Therapies in the Treatment of HER2-Overexpressing Breast Cancer

    Human Epidermal Growth Factor Receptor Family-Targeted Therapies in the Treatment of HER2-Overexpressing Breast Cancer od Zeynep Eroglu, Tomoko Tagawa, George Somlo

    Izdano 2014
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  3. 3
    Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy

    Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy od James Sun, Jonathan S. Zager, Zeynep Eroglu

    Izdano 2018
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  4. 4
    Translational pathology, genomics and the development of systemic therapies for acral melanoma

    Translational pathology, genomics and the development of systemic therapies for acral melanoma od Y. Ann Chen, Jamie K. Teer, Zeynep Eroglu, Jheng-Yu Wu, John M. Koomen, Florian A. Karreth, Jane L. Messina, Keiran S.M. Smalley

    Izdano 2019
    Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  5. 5
    Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction

    Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction od Bridgette A. Kanz, Megan H. Pollack, Romany Johnpulle, Igor Puzanov, Leora Horn, Alicia K. Morgans, Jeffrey A. Sosman, Suthee Rapisuwon, Robert M. Conry, Zeynep Eroglu, Douglas B. Johnson

    Izdano 2016
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  6. 6
    Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab

    Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab od Zeynep Eroglu, Dae Won Kim, Xiaoyan Wang, Luis H. Camacho, Bartosz Chmielowski, Elizabeth Seja, Arturo Villanueva, Kathleen Ruchalski, John A. Glaspy, Kevin B. Kim, Wen-Jen Hwu, Antoni Ribas

    Izdano 2015
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  7. 7
    Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma

    Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma od Megan H. Pollack, Allison Betof Warner, Helen Dearden, K. Rapazzo, Ian Valentine, Andrew S. Brohl, Kristin Kathleen Ancell, Georgina V. Long, Alexander M. Menzies, Zeynep Eroglu, Douglas B. Johnson, Alexander N. Shoushtari

    Izdano 2017
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  8. 8
    Clinical Features of Acquired Resistance to Anti–PD-1 Therapy in Advanced Melanoma

    Clinical Features of Acquired Resistance to Anti–PD-1 Therapy in Advanced Melanoma od Daniel Wang, Zeynep Eroglu, Alpaslan Özgün, Paul Leger, Shilin Zhao, Fei Ye, Jason J. Luke, Richard W. Joseph, Rizwan Haq, Patrick A. Ott, F. Stephen Hodi, Jeffrey A. Sosman, Douglas B. Johnson, Elizabeth I. Buchbinder

    Izdano 2017
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  9. 9
    Circulating tumor DNA‐based molecular residual disease detection for treatment monitoring in advanced melanoma patients

    Circulating tumor DNA‐based molecular residual disease detection for treatment monitoring in advanced melanoma patients od Zeynep Eroglu, Shifra Krinshpun, Ekaterina Kalashnikova, Sumedha Sudhaman, Turkan Ozturk Topcu, Matt Nichols, Justin Martin, Katherine Bui, Charuta C. Palsuledesai, Meenakshi Malhotra, Perry Olshan, Joseph Markowitz, Nikhil I. Khushalani, Ahmad A. Tarhini, Jane L. Messina, Alexey Aleshin

    Izdano 2023
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  10. 10
    Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy

    Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy od Eileen Shiuan, Kathryn E. Beckermann, Alpaslan Özgün, Ciara M. Kelly, Meredith McKean, Jennifer L. McQuade, Mary Ann Thompson, Igor Puzanov, John P. Greer, Suthee Rapisuwon, Michael A. Postow, Michael A. Davies, Zeynep Eroglu, Douglas B. Johnson

    Izdano 2017
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  11. 11
    Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study

    Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study od Helen Gogas, Brigitte Dréno, James Larkin, Lev Demidov, Daniil Stroyakovskiy, Zeynep Eroglu, Pier Francesco Ferrucci, Jacopo Pigozzo, Piotr Rutkowski, Jacek Mackiewicz, Isabelle Rooney, Athina Voulgari, Sarah M. Troutman, Bethany Pitcher, Guo Yu, Y. Yan, Marília Germanos de Castro, S. Mulla, Keith T. Flaherty, Ana Arance

    Izdano 2020
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  12. 12
    Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies

    Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies od Alain P. Algazi, Katy K. Tsai, Alexander N. Shoushtari, Rodrigo Ramella Munhoz, Zeynep Eroglu, Josep M. Piulats, Patrick A. Ott, Douglas B. Johnson, Jimmy J. Hwang, Adil Daud, Jeffrey A. Sosman, Richard D. Carvajal, Bartosz Chmielowski, Michael A. Postow, Jeffrey S. Weber, Ryan J. Sullivan

    Izdano 2016
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  13. 13
    Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma

    Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma od John E. Mullinax, MacLean Hall, Sangeetha Prabhakaran, Jeffrey S. Weber, Nikhil I. Khushalani, Zeynep Eroglu, Andrew S. Brohl, Joseph Markowitz, Erica Royster, Allison Richards, Valerie E. Stark, Jonathan S. Zager, Linda Kelley, Cheryl A. Cox, Vernon K. Sondak, James J. Mulé, Shari Pilon‐Thomas, Amod A. Sarnaik

    Izdano 2018
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  14. 14
    The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy

    The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy od Todd C. Knepper, Meagan Montesion, Jeffery S. Russell, Ethan S. Sokol, Garrett M. Frampton, Vincent A. Miller, Lee A. Albacker, Howard L. McLeod, Zeynep Eroglu, Nikhil I. Khushalani, Vernon K. Sondak, Jane L. Messina, Michael J. Schell, James A. DeCaprio, Kenneth Y. Tsai, Andrew S. Brohl

    Izdano 2019
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  15. 15
    Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma

    Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma od Inna Smalley, Eunjung Kim, Jiannong Li, Paige Spence, Clayton Wyatt, Zeynep Eroglu, Vernon K. Sondak, Jane L. Messina, Nalan Akgül Babacan, Silvya Stuchi Maria‐Engler, Lesley de Armas, Siôn L. Williams, Robert A. Gatenby, Y. Ann Chen, Alexander R.A. Anderson, Keiran S.M. Smalley

    Izdano 2019
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  16. 16
    Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific

    Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific od Joseph J. Sacco, Peter Kirk, Emma Leach, Alexander N. Shoushtari, Richard D. Carvajal, Camille Britton-Rivet, Sophie Khakoo, Laura C. Collins, Luis de la Cruz‐Merino, Zeynep Eroglu, Alexandra P. Ikeguchi, Paul Nathan, Omid Hamid, Marcus O. Butler, Sarah Stanhope, Koustubh Ranade, Takami Sato

    Izdano 2025
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  17. 17
    Long-Term Outcomes in Patients With <i>BRAF</i> V600–Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib

    Long-Term Outcomes in Patients With <i>BRAF</i> V600–Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib od Georgina V. Long, Zeynep Eroglu, Jeffrey R. Infante, Sapna P. Patel, Adil Daud, Douglas B. Johnson, René González, Richard Kefford, Omid Hamid, Lynn M. Schuchter, Jonathan Cebon, William H. Sharfman, Robert R. McWilliams, Mario Sznol, Suman Redhu, Eduard Gasal, Bijoyesh Mookerjee, Jeffrey S. Weber, Keith T. Flaherty

    Izdano 2017
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  18. 18
    Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma

    Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma od Daniel J. Olson, Zeynep Eroglu, Bruce Brockstein, Andrew Poklepovic, Madhuri Bajaj, Sunil Babu, Sigrun Hallmeyer, Mario R. Velasco, Jose Lutzky, Emily F. Higgs, Riyue Bao, Timothy Carll, Brian Labadie, Thomas Krausz, Yuanyuan Zha, Theodore Karrison, Vernon K. Sondak, Thomas F. Gajewski, Nikhil I. Khushalani, Jason J. Luke

    Izdano 2021
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  19. 19
    Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

    Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab od Alexander M. Menzies, Douglas B. Johnson, Sangeetha Ramanujam, Victoria Atkinson, Annie Wong, John Park, Jennifer L. McQuade, Alexander N. Shoushtari, Katy K. Tsai, Zeynep Eroglu, Oliver Klein, Jessica C. Hassel, Jeffrey A. Sosman, Alexander Guminski, Ryan J. Sullivan, Antoni Ribas, Matteo S. Carlino, Michael A. Davies, Shahneen Sandhu, Georgina V. Long

    Izdano 2016
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  20. 20
    Combined BRAF and HSP90 Inhibition in Patients with Unresectable <i>BRAF</i>V600E-Mutant Melanoma

    Combined BRAF and HSP90 Inhibition in Patients with Unresectable <i>BRAF</i>V600E-Mutant Melanoma od Zeynep Eroglu, Y. Ann Chen, Geoffrey T. Gibney, Jeffrey S. Weber, Ragini R. Kudchadkar, Nikhil I. Khushalani, Joseph Markowitz, Andrew S. Brohl, Leticia Tetteh, Howida Ramadan, Gina Arnone, Jiannong Li, Xiuhua Zhao, Ritin Sharma, Lancia Darville, Bin Fang, Inna Smalley, Jane L. Messina, John M. Koomen, Vernon K. Sondak, Keiran S.M. Smalley

    Izdano 2018
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:

Iskalna orodja: